These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28754116)

  • 1. How is disease severity associated with quality of life in psoriasis patients? Evidence from a longitudinal population-based study in Sweden.
    Geale K; Henriksson M; Schmitt-Egenolf M
    Health Qual Life Outcomes; 2017 Jul; 15(1):151. PubMed ID: 28754116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients.
    Norlin JM; Steen Carlsson K; Persson U; Schmitt-Egenolf M
    Br J Dermatol; 2012 Apr; 166(4):797-802. PubMed ID: 22182212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.
    Hjalte F; Carlsson KS; Schmitt-Egenolf M
    Br J Dermatol; 2018 Jan; 178(1):245-252. PubMed ID: 28644904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.
    Pickard AS; Gooderham M; Hartz S; Nicolay C
    J Med Econ; 2017 Jan; 20(1):19-27. PubMed ID: 27471948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients.
    Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
    Am J Clin Dermatol; 2017 Aug; 18(4):583-590. PubMed ID: 28342016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
    Davison NJ; Thompson AJ; Turner AJ; Longworth L; McElhone K; Griffiths CEM; Payne K;
    Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients.
    Poór AK; Rencz F; Brodszky V; Gulácsi L; Beretzky Z; Hidvégi B; Holló P; Kárpáti S; Péntek M
    Qual Life Res; 2017 Dec; 26(12):3409-3419. PubMed ID: 28875430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
    Norlin JM; Carlsson KS; Persson U; Schmitt-Egenolf M
    BioDrugs; 2015 Dec; 29(6):389-98. PubMed ID: 26670179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Assessment of health-related quality of life in psoriasis patients in Hungary].
    Poór AK; Sárdy M; Cserni T; Brodszky V; Holló P; Gulácsi L; Remenyik É; Szegedi A; Rencz F; Péntek M
    Orv Hetil; 2018 May; 159(21):837-846. PubMed ID: 29779387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy.
    Norlin JM; Calara PS; Persson U; Schmitt-Egenolf M
    J Dermatolog Treat; 2017 Sep; 28(6):500-504. PubMed ID: 28132580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice.
    Norlin JM; Steen Carlsson K; Persson U; Schmitt-Egenolf M
    Dermatology; 2012; 225(4):326-32. PubMed ID: 23328678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Changes in Psoriasis Area and Severity Index by Body Region on Quality of Life in Patients with Psoriasis.
    Sojević Timotijević Z; Majcan P; Trajković G; Relić M; Novaković T; Mirković M; Djurić S; Nikolić S; Lazić B; Janković S
    Acta Dermatovenerol Croat; 2017 Oct; 25(3):215-222. PubMed ID: 29252174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.
    Norlin JM; Nilsson K; Persson U; Schmitt-Egenolf M
    Br J Dermatol; 2020 Apr; 182(4):965-973. PubMed ID: 31325318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health status and quality of life in patients with psoriasis: an Iranian cross-sectional survey.
    Moradi M; Rencz F; Brodszky V; Moradi A; Balogh O; Gulácsi L
    Arch Iran Med; 2015 Mar; 18(3):153-9. PubMed ID: 25773688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary.
    Herédi E; Rencz F; Balogh O; Gulácsi L; Herszényi K; Holló P; Jókai H; Kárpáti S; Péntek M; Remenyik É; Szegedi A; Brodszky V
    Eur J Health Econ; 2014 May; 15 Suppl 1():S111-9. PubMed ID: 24832842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
    Chaptini C; Quinn S; Marshman G
    Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI).
    Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
    J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):452-6. PubMed ID: 24911993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment satisfaction, willingness to pay and quality of life in Japanese patients with psoriasis.
    Masaki S; Tatsukawa R; Uryu M; Takahara M; Furue M; Ohata C; Nakama T; Hino R; Nakamura M; Nakayama J; Imafuku S
    J Dermatol; 2017 Feb; 44(2):143-146. PubMed ID: 27599656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis.
    Luger TA; Barker J; Lambert J; Yang S; Robertson D; Foehl J; Molta CT; Boggs R
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):896-904. PubMed ID: 19453794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis.
    Bergstrom KG; Arambula K; Kimball AB
    Cutis; 2003 Nov; 72(5):407-11. PubMed ID: 14655784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.